GlassScriptPhysician profile
Mohammad Salman Khan
NPI 1760610919
$388,451.87
in general payments reported to CMS, 2019-2025
45 companies · $68K in 2025
The $68K reported for 2025 was more than what 98% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19K · 2020: $38K · 2021: $52K · 2022: $47K · 2023: $88K · 2024: $75K · 2025: $68K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $210K · Food and Beverage: $8,920 · Travel and Lodging: $7,425 · Consulting Fee: $5,525 · Education: $17.85 · Gift: $17.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $209,625.00 |
| Food and Beverage | $8,920.31 |
| Travel and Lodging | $7,425.18 |
| Consulting Fee | $5,525.00 |
| Education | $17.85 |
| Gift | $17.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $381,360.10 | 2019-2025 | Arexvy, Nucala, Trelegy Ellipta |
| Viiv Healthcare Company | $1,600.00 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $1,068.94 | 2019-2025 | Fasenra, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $643.80 | 2019-2025 | Ofev, Stiolto Respimat, Jascayd |
| United Therapeutics Corporation | $629.58 | 2019-2025 | Tyvaso |
| Jazz Pharmaceuticals INC. | $350.07 | 2020-2025 | Xywav |
| Actelion Pharmaceuticals US, INC. | $267.91 | 2020-2024 | Opsumit |
| Regeneron Healthcare Solutions, INC. | $265.32 | 2019-2025 | Dupixent |
| Csl Behring | $228.87 | 2021-2025 | Haegarda, Andembry, Kcentra |
| Genzyme Corporation | $224.50 | 2020-2025 | |
| Mylan Specialty L.P. | $193.61 | 2019-2023 | Yupelri |
| Sanofi-Aventis U.S. LLC | $124.69 | 2023 | |
| Genentech USA, INC. | $111.94 | 2019-2025 | Xolair |
| Merck Sharp & Dohme LLC | $102.74 | 2019-2024 | Zerbaxa, Dificid, Recarbrio |
| Harmony Biosciences LLC | $102.17 | 2021-2024 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.